journal
https://read.qxmd.com/read/38583451/tapering-conventional-synthetic-dmards-towards-sustained-drug-free-remission-in-rheumatoid-arthritis
#1
JOURNAL ARTICLE
Elise van Mulligen
No abstract text is available yet for this article.
April 4, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38583450/effects-of-tapering-conventional-synthetic-disease-modifying-antirheumatic-drugs-to-drug-free-remission-versus-stable-treatment-in-rheumatoid-arthritis-arctic-rewind-3-year-results-from-an-open-label-randomised-controlled-non-inferiority-trial
#2
JOURNAL ARTICLE
Kaja E Kjørholt, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge C Olsen, Hallvard Fremstad, Cristina Spada, Tor Magne Madland, Christian A Høili, Gunnstein Bakland, Åse Lexberg, Inger Johanne Widding Hansen, Inger Myrnes Hansen, Hilde Haukeland, Maud-Kristine Aga Ljoså, Ellen Moholt, Till Uhlig, Tore K Kvien, Daniel H Solomon, Désirée van der Heijde, Espen A Haavardsholm, Siri Lillegraven
BACKGROUND: Tapering of disease-modifying antirheumatic drugs (DMARDs) to drug-free remission is an attractive treatment goal for patients with rheumatoid arthritis, although long-term effects of tapering and withdrawal remain unclear. We compared 3-year risks of flare between three conventional synthetic DMARD treatment strategies in patients with rheumatoid arthritis in sustained remission. METHODS: In this open-label, randomised controlled, non-inferiority trial, we enrolled patients aged 18-80 years with rheumatoid arthritis who had been in sustained remission for at least 1 year on stable conventional synthetic DMARD therapy...
April 4, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574747/cranial-involvement-in-giant-cell-arteritis
#3
REVIEW
Philipp Bosch, Georgina Espigol-Frigolé, Maria C Cid, Susan P Mollan, Wolfgang A Schmidt
Since its first clinical description in 1890, extensive research has advanced our understanding of giant cell arteritis, leading to improvements in both diagnosis and management for affected patients. Imaging studies have shown that the disease frequently extends beyond the typical cranial arteries, also affecting large vessels such as the aorta and its proximal branches. Meanwhile, advances in comprehending the underlying pathophysiology of giant cell arteritis have given rise to numerous potential therapeutic agents, which aim to minimise the need for glucocorticoid treatment and prevent flares...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574746/fibrotic-phenotype-of-igg4-related-disease
#4
REVIEW
Marco Lanzillotta, Emma Culver, Amita Sharma, Yoh Zen, Wen Zhang, John H Stone, Emanuel Della-Torre
A prompt response to glucocorticoids is a clinical hallmark of IgG4-related disease. However, manifestations characterised by prominent tissue fibrosis on histological examination can be less responsive to glucocorticoid therapy than other types of IgG4-related disease. These manifestations include retroperitoneal fibrosis, fibrosing mediastinitis, Riedel thyroiditis, orbital pseudotumor, and hypertrophic pachymeningitis, among others. To explain this discrepancy, a preliminary distinction into proliferative and fibrotic phenotypes of IgG4-related disease has been proposed on the basis of clinical presentation, pathological features, and response to immunosuppressive therapy...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574745/large-vessel-giant-cell-arteritis
#5
REVIEW
Kornelis S M van der Geest, Maria Sandovici, Thorsten A Bley, James R Stone, Riemer H J A Slart, Elisabeth Brouwer
Giant cell arteritis is the principal form of systemic vasculitis affecting people over 50. Large-vessel involvement, termed large vessel giant cell arteritis, mainly affects the aorta and its branches, often occurring alongside cranial giant cell arteritis, but large vessel giant cell arteritis without cranial giant cell arteritis can also occur. Patients mostly present with constitutional symptoms, with localising large vessel giant cell arteritis symptoms present in a minority of patients only. Large vessel giant cell arteritis is usually overlooked until clinicians seek to exclude it with imaging by ultrasonography, magnetic resonance angiography (MRA), computed tomography angiography (CTA), or [18 F]fluorodeoxyglucose-PET-CT...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574744/proliferative-features-of-igg4-related-disease
#6
REVIEW
Guy Katz, Yasmin Hernandez-Barco, Diego Palumbo, Thomas V Guy, Lingli Dong, Cory A Perugino
IgG4-related disease is an immune-mediated disease that can lead to substantial morbidity and organ damage. Capable of affecting nearly any organ system or anatomic site, and showing considerable overlap in clinical presentation with various other diseases, IgG4-related disease often poses a diagnostic challenge for clinicians. Furthermore, there are no diagnostic biomarkers with high specificity for IgG4-related disease, and histopathological examination is nuanced and requires clinical correlation for accurate diagnosis...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574743/myeloperoxidase-specific-antineutrophil-cytoplasmic-antibody-associated-vasculitis
#7
REVIEW
Sabrina Arnold, A Richard Kitching, Veronique Witko-Sarsat, Thorsten Wiech, Ulrich Specks, Sebastian Klapa, Sara Comdühr, Anja Stähle, Antje Müller, Peter Lamprecht
Myeloperoxidase (MPO)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (MPO-ANCA-associated vasculitis) is one of two major ANCA-associated vasculitis variants characterised by systemic necrotising vasculitis with few or no immune deposits. MPO-ANCA-associated vasculitis predominantly affects small blood vessels and, in contrast to its counterpart proteinase 3-ANCA-associated vasculitis, is generally not associated with granulomatous inflammation. The kidneys and lungs are the most commonly affected organs...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574742/proteinase-3-specific-antineutrophil-cytoplasmic-antibody-associated-vasculitis
#8
REVIEW
Samuel D Falde, Lynn A Fussner, Henry D Tazelaar, Erin K O'Brien, Peter Lamprecht, Maximilian F Konig, Ulrich Specks
Proteinase 3 (PR3)-specific antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is one of two major ANCA-associated vasculitis variants and is pathogenically linked to granulomatosis with polyangiitis (GPA). GPA is characterised by necrotising granulomatous inflammation that preferentially affects the respiratory tract. The small vessel vasculitis features of GPA are shared with microscopic polyangiitis. Necrotising granulomatous inflammation of GPA can lead to PR3-ANCA and small vessel vasculitis via activation of neutrophils and monocytes...
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38574741/celebrating-progress-in-the-vasculitides-old-and-new
#9
JOURNAL ARTICLE
John H Stone
No abstract text is available yet for this article.
March 28, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38554720/development-of-a-diagnostic-prediction-model-for-giant-cell-arteritis-by-sequential-application-of-southend-giant-cell-arteritis-probability-score-and-ultrasonography-a-prospective-multicentre-study
#10
JOURNAL ARTICLE
Alwin Sebastian, Kornelis S M van der Geest, Alessandro Tomelleri, Pierluigi Macchioni, Giulia Klinowski, Carlo Salvarani, Diana Prieto-Peña, Edoardo Conticini, Muhammad Khurshid, Lorenzo Dagna, Elisabeth Brouwer, Bhaskar Dasgupta
BACKGROUND: Giant cell arteritis is a critically ischaemic disease with protean manifestations that require urgent diagnosis and treatment. European Alliance of Associations for Rheumatology (EULAR) recommendations advocate ultrasonography as the first investigation for suspected giant cell arteritis. We developed a prediction tool that sequentially combines clinical assessment, as determined by the Southend Giant Cell Arteritis Probability Score (SGCAPS), with results of quantitative ultrasonography...
March 27, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38554719/improvement-of-a-giant-cell-arteritis-prediction-model
#11
JOURNAL ARTICLE
Zandra E Walton, Naomi J Patel
No abstract text is available yet for this article.
March 27, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38552652/how-can-trial-designs-better-serve-the-needs-of-children-and-young-people-with-juvenile-idiopathic-arthritis
#12
REVIEW
Freya Luling Feilding, Laura Crosby, Emily Earle, Richard Beesley, Kerry Leslie, Eilean MacDonald, Catherine Wright, Debbie Wilson, Anna Sherriffs, Teresa Duerr, Athimalaipet V Ramanan
In juvenile idiopathic arthritis we have seen remarkable progress in the number of available licensed biological and small molecule treatments in the past two decades, leading to improved outcomes for patients. Designing clinical trials for these therapeutics is fraught with ethical, legislative, and practical challenges. However, many aspects of current clinical trial design in juvenile idiopathic arthritis do not meet the needs of patients and clinicians. Commonly used withdrawal trial designs raise substantial ethical concerns for patients and families who believe that they do not enable evidence-based and patient-centred decisions around medication choices...
March 26, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38458209/analgesic-effectiveness-after-total-hip-arthroplasty
#13
JOURNAL ARTICLE
Paul S Myles, Susan M Liew
No abstract text is available yet for this article.
March 5, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38458208/non-opioid-analgesic-combinations-following-total-hip-arthroplasty-recipe-a-randomised-placebo-controlled-blinded-multicentre-trial
#14
JOURNAL ARTICLE
Joakim Steiness, Daniel Hägi-Pedersen, Troels Haxholdt Lunn, Søren Overgaard, Stig Brorson, Ben Kristian Graungaard, Martin Lindberg-Larsen, Claus Varnum, Lars Hyldborg Lundstrøm, Torben Beck, Michael Skettrup, Niels Anker Pedersen, Manuel Josef Bieder, Adam Gregers von Cappeln, Lina Pleckaitiene, Peter Lindholm, Syed Shaheer Haider Bukhari, Cecilie Bauer Derby, Maria Gantzel Nielsen, Oskar Wilborg Exsteen, Louise Ørts Vinstrup, Kasper Højgaard Thybo, Kasper Smidt Gasbjerg, Anders Kehlet Nørskov, Janus Christian Jakobsen, Ole Mathiesen
BACKGROUND: Multimodal postoperative analgesia following total hip arthroplasty is recommended, but the optimal combination of drugs remains uncertain. The aim of the RECIPE trial was to investigate the relative benefit and harm of the different combinations of paracetamol, ibuprofen, and the analgesic adjuvant dexamethasone for treatment of postoperative pain following total hip arthroplasty. METHODS: The RECIPE trial was a randomised, blinded, placebo-controlled trial conducted at nine Danish hospitals...
March 5, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38423029/brachial-plexopathy-an-unusual-manifestation-of-takayasu-arteritis
#15
JOURNAL ARTICLE
Nayan Patel Sureja, Pusapati Venkata Ramachandra Raju, Ashish Rajendra Ghuli
No abstract text is available yet for this article.
February 26, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38423028/a-preoperative-package-of-care-for-osteoarthritis-consisting-of-weight-loss-orthotics-rehabilitation-and-topical-and-oral-analgesia-opportunity-a-two-centre-open-label-randomised-controlled-feasibility-trial
#16
JOURNAL ARTICLE
A Hamish R W Simpson, Nicholas D Clement, Sharon A Simpson, Hemandt Pandit, Susie Smillie, Anthony R Leeds, Philip G Conaghan, Sarah R Kingsbury, David Hamilton, Peter Craig, David Ray, Catriona Keerie, Elaine Kinsella, Anna Bell-Higgs, Arlene McGarty, Christine Beadle, Colin R Howie, John Norrie
BACKGROUND: Osteoarthritis of the knee is a major cause of disability worldwide. Non-operative treatments can reduce the morbidity but adherence is poor. We hypothesised that adherence could be optimised if behavioural change was established in the preoperative period. Therefore, we aimed to assess feasibility, acceptability, and recruitment and retention rates of a preoperative package of non-operative care in patients awaiting knee replacement surgery. METHODS: We did an open-label, randomised controlled, feasibility trial in two secondary care centres in the UK...
February 26, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38402892/therapeutic-drug-monitoring-countering-the-effect-of-anti-infliximab-antibodies
#17
JOURNAL ARTICLE
Femke Hooijberg, Gertjan Wolbink
No abstract text is available yet for this article.
February 22, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38330989/correction-to-lancet-rheumatol-2024-6-e40-50
#18
(no author information available yet)
No abstract text is available yet for this article.
February 5, 2024: Lancet Rheumatology
https://read.qxmd.com/read/38508821/toxic-epidermal-necrosis-like-acute-cutaneous-lupus-erythematosus
#19
JOURNAL ARTICLE
Koji Suzuki, Shuntaro Saito, Mitsuhiro Akiyama, Yasushi Kondo, Jun Kikuchi, Hironari Hanaoka, Yuko Kaneko
No abstract text is available yet for this article.
April 2024: Lancet Rheumatology
https://read.qxmd.com/read/38508820/not-growing-out-of-it
#20
JOURNAL ARTICLE
Nan Fletcher-Lloyd
No abstract text is available yet for this article.
April 2024: Lancet Rheumatology
journal
journal
58309
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.